The three new programs disclosed today are from Relay Therapeutics’ existing pre-clinical pipeline. The continued advancement of these programs has already been accounted for in the company’s existing cash runway guidance. As of March 31, 2024, cash, cash equivalents and investments totaled approximately $750 million and are expected to fund the current operating plan into the second half of 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLAY:
- Relay Therapeutics Discloses Three New Programs at New Program & Platform Event
- Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608
- Relay Therapeutics to Participate in Upcoming Investor Conferences
- Relay Therapeutics to Host New Program and Platform Event on June 6, 2024
- Relay Therapeutics to host New Program and Platform event